The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Dendrimers and Polymer Drug Conjugates Market, 2016 - 2026

  • Lowest Price Guaranteed From USD 2,349

  • Published
    June 2016

  • Pages
    183

  • View Count
    630

Example Insights

  1. Nearly 40 polymer drug conjugates are currently in clinical and preclinical stages of development; molecules in phase III and II account for nearly 19% of the pipeline while 26% is captured by molecules in phase I/II and I.
  2. There are several types of dendrimers being used for both commercial and research purposes in the pharmaceutical domain; the dendrimers most widely used for industry applications include PAMAM, PLL, Priostar®, Astramol®. However, with over 4000 papers published between 2006 and 2016 (as reported in PubMed), dendrimers are being extensively explored by researchers in the non-industry / academic institutes.
  3. With one commercialized therapeutic product (VivaGel®) and several other marketed dendrimer-based products (SuperFect®, Stratus® CS, PrioFect™, Alert Ticket™), Starpharma has emerged as a forerunner in the dendrimer market.
  4. Amongst the different biomedical applications that dendrimers and polymer drug conjugates serve, drug delivery holds a large opportunity. Several big pharma players as AstraZeneca, Eli Lilly, GSK’s Stiefel have collaborated with dendrimer technology developers (such as DEP® Technology by Starpharma) to improve the therapeutic efficacy and drug delivery properties of their existing products. Additionally, polymer drug conjugates have expanded their focus to a broad range of diseases exploring different routes of administrations for better drug delivery.
  5. The polymer drug conjugates market momentum will be driven by the success of current batch of late stage clinical molecules; these primarily include NKTR-181 (by Nektar Therapeutics), NKTR-102 (by Nektar Therapeutics), CRLX101 (by Cerulean Pharma) and Opaxio™ (by CTI BioPharma).
  6. Specific molecules such as NKTR-181 and NKTR-102 are anticipated to achieve a block buster status in the near future. With eight molecules (two mentioned above and six others in lower stages of development) in development, Nektar Therapeutics is expected to play an important role in the market’s evolution.

Overview

As defined by the National Nanotechnology Initiative, nanotechnology is the branch of science that deals with materials smaller than 100 nanometers. Nanomedicines are nano-sized particles that help in the diagnosis, treatment and monitoring of therapeutic agents. The discovery of several nanocarriers such as polymers, proteins, micelles, dendrimers, liposomes, emulsions, nanoparticles, each with a unique structure, has provided the drug developers with options to improve the pharmacokinetics and release properties of their existing drugs.

Within the biomedical sector, nanocarriers have an array of therapeutic and diagnostic applications. These include drug delivery, targeted therapy, gene therapy, development of diagnostic assays, molecular imaging and a number of research applications. Specifically, drug delivery has emerged as one of the most popular applications that enhances the therapeutic efficacy of biomolecules. Several competing drug delivery approaches are being explored for their efficacy with various routes of administration.

Dendrimers, owing to their structural flexibility, hold potential for several medical and non-medical applications; however, their use in the biomedical field is yet to be fully explored. Several academic institutes and organizations are conducting intense research to explore the therapeutic and diagnostic potential of dendrimers. With a number of commercial dendrimers-based products (both biomedical and agro-based), Starpharma is a prominent player in this domain.

On the other hand, polymer drug conjugates is a well-established segment with several commercialized products. The current polymer drug conjugates market has over 10 approved drug candidates for a wide range of molecular targets and disease areas. Examples include (in alphabetical order) Adynovate by Baxalta, Doxil®  by Pfizer / Sun Pharmaceuticals, Krystexxa® by Savient Pharmaceuticals / Crealta Pharmaceuticals, Movantik™ by AstraZeneca, Oncospar® by Enzon Pharmaceuticals, Plegridy® by Biogen. Despite an already well-established market, the field has gathered interest of several other players to explore the complete potential of polymer drug conjugates in different therapeutic areas. The clinical outcomes and the success of the current clinical molecules will decide the fate of the future market.

 

Scope of the Report

The “Dendrimers and Polymer Drug Conjugates Market, 2016-2026” report delivers a comprehensive study on the emergence of nanocarriers as a significant tool for drug delivery, therapeutics and diagnostics. For the purpose of this report, we have primarily focused on the following two types of nanocarriers.

  • Dendrimers
  • Polymer drug conjugates

Dendrimers, the nanoscale hyper-branched structures, are evolving in the healthcare sector to enhance the properties of existing therapeutic compounds as well as for introduction of novel therapeutic/diagnostic products. VivaGel® by Starpharma is a commercially available therapeutic product; in addition, transfection kits and diagnostic assays are also available. However, from a commercial perspective, market of dendrimers is still in its infancy within the biomedical sector. The domain is gradually gaining traction with several technologies and approaches being designed for improving drug release properties. In addition to drug delivery, which is the key application area, some other potential applications of dendrimers being actively pursued in research include disease diagnosis, targeted therapy, MRI imaging, tissue regeneration, cell repair and vaccine development. 

A parallel field of polymer therapeutics includes introduction of polymers with conventional drugs; these are more commonly known as polymer drug conjugates. Conjugation of drugs with polymers has demonstrated a marked improvement in their efficacy and release profiles. For the purpose of our study, we have included the molecules in the clinical/preclinical development (defined as per the Ringsdorf Model). Numerous polymer drug conjugates have already been commercialized for a wide range of therapeutic areas; our study provides an analysis of key disease areas being targeted by the developers of polymer drug conjugates. Several well-known anti-cancer drugs such as docetaxel, paclitaxel and doxorubicin have been conjugated with polymers such as PEG, HPMA and PLA to enhance their water solubility, half-life, efficacy and body clearance.

The report assesses key drivers that have governed the evolution of polymer drug conjugates over the past several years and determines the market in a long term (2016-2026). The research, analysis and insights presented in this report include potential sales of the drugs in phase III and phase II of development. To add robustness to our forecast model, we have provided three market scenarios. The conservative, base and optimistic scenarios represent three different tracks of market evolution. In addition, we have provided a detailed discussion on the future trends and the key opportunity areas for dendrimers that are likely to shape the market in the coming years.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the report. It offers a high level view on the present scenario of dendrimers and polymer drug conjugates and where they are headed in the mid to long term.

Chapter 3  provides a general introduction to nanotechnology with a detailed discussion on its applications in the biopharmaceutical industry. This chapter discusses the various types of nanocarriers that have revolutionized drug delivery and other biomedical applications.

Chapter 4  includes information on nearly 40 polymer drug conjugates that are being evaluated in different stages of development (both clinical and preclinical/discovery). In this chapter, we have identified the companies that are active in this market and conducted a detailed pipeline analysis including information on type of polymers, type of drugs, most commonly targeted indications and the phase of development. In addition, we have provided a list of the different classes of dendrimers highlighting their developer, core molecules and surface groups.

Chapter 5  provides an in-depth introduction to dendrimers. In this chapter, we have captured the most popular dendrimers used for development of diagnostics, therapeutics and other biomedical products; these are accompanied with detailed information on their structure, research applications and detailed product profiles of the commercialized products.

Chapter 6  comprises of a comprehensive discussion on the advantages, applications and target disease areas of polymer drug conjugates. In addition, the chapter gives detailed profiles of phase III and phase II molecules including information of their developer, clinical trials and primary/secondary endpoints.

Chapter 7  offers a comprehensive view on the market forecast of polymer drug conjugates measuring the opportunity in the next ten years. Due to the uncertainty surrounding some of the key assumptions, we have presented three different evolution scenarios for the overall market. In addition, we have presented a qualitative analysis of the opportunity areas of dendrimers highlighting their future potential.

Chapter 8  summarizes the overall report. In this chapter, we have provided a recap of the key take aways and our overall opinion on where the market is headed in the mid-long term.

Chapter 9  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 10  is an appendix, which provides a list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. The Concept of Nanotechnology
3.2. Nanomedicine: A Potential Platform for Therapeutic Applications
3.3. Applications of Nanomedicine
3.3.1. Drug Delivery
3.3.2. Diagnostic Techniques
3.3.3. Anti-Microbial Techniques
3.3.4. Therapeutic Techniques
3.3.5. Surgery
3.3.6. Gene Therapy
3.3.7. Imaging
3.4. Nanocarriers: Important Tools for Nanomedicine
3.4.1. Nanoparticles
3.4.2. Carbon Nanotubes (CNTs)
3.4.3. Polymer Conjugates
3.4.4. Nanocrystals
3.4.5. Dendrimers
3.5. Nanocarriers and Drug Approvals
 
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Dendrimers: Product List and Classes
4.3. Polymer Drug Conjugates: Development Pipeline
4.3.1. Distribution by Phase of Development
4.3.2. Distribution by Type of Disease Area
4.3.3. Distribution by Type of Polymer
4.3.4. Distribution by Type of Drug
4.3.5. Leading Players of the Industry
 
5.DENDRIMERS: A DETAILED REVIEW
5.1. An Introduction to Dendrimers
5.2. Synthesis of Dendrimers
5.2.1. Divergent Mode of Synthesis
5.2.2. Convergent Mode of Synthesis
5.3. Characterization of Dendrimers
5.3.1. Spectroscopic Techniques
5.3.2. Microscopy
5.3.3. Size Exclusion Chromatography
5.3.4. Other Techniques
5.4. Properties of Dendrimers
5.5. Advantages of Dendrimers
5.6. Applications of Dendrimers
5.6.1. Drug Delivery
5.6.2. Mimics of Globular Proteins
5.6.3. Gene Transfection
5.6.4. Imaging and Diagnostics
5.6.5. Solubility Enhancers
5.6.6. Modification of Electrodes
5.6.7. Development of Vaccines
5.7. Classification of Dendrimers
5.8. Types of Dendrimers
5.9. Commercialized Dendrimers
5.9.1. PAMAM/Starburst®
5.9.1.1. Specifications
5.9.1.2. Structure and Synthesis
5.9.1.3. Properties
5.9.1.4. Products Based on PAMAM
5.9.1.5. PAMAM: Application in Biopharmaceuticals
5.9.2. Poly-L-Lysine (PLL) Dendrimers (Multiple Antigen Peptide Dendrimers)
5.9.2.1. Specifications
5.9.2.2. Structure
5.9.2.3. Products Based on PLL Dendrimers
5.9.3. Priostar® Dendrimers (Frechet Type Dendrimers)
5.9.3.1. Specifications
5.9.3.2. Priostar® : Applications
5.9.3.3. Products Based on Priostar® Dendrimers
5.9.4. Astramol® (Polypropylenimine (PPI) Dendrimer)
5.9.4.1. Specifications
 

6.POLYMER DRUG CONJUGATES: DRUG PROFILES
6.1. The Rationale of Polymer Drug Conjugates
6.2. Designing and Characterization of Polymer Drug Conjugates
6.3. Most Common Polymers
6.4. Most Common Drugs
6.5. Advantages of Polymer Drug Conjugates
6.6. Polymer Drug Conjugates in Oncology and Other Diseases
 
6.7. Polymer Drug Conjugates: Drug Profiles
6.7.1. Nektar Therapeutics
6.7.1.1. Company Overview
6.7.1.2. Product Profile: NKTR-102 / EtirinotecanPegol
6.7.1.3. Product Profile: NKTR-181
 
6.7.2. CTI BioPharma
6.7.2.1. Company Overview
6.7.2.2. Product Profile: Opaxio™
 
6.7.3. Cerulean Pharma
6.7.3.1. Company Overview
6.7.3.2. Product Profile: CRLX101
 
7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Chapter Overview
7.2. Polymer Drug Conjugates: Future Projections
7.2.1. Scope and Limitations
7.2.2. Forecast Methodology
7.2.3. Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
7.2.3.1. NKTR-118 (Nektar Therapeutics)
7.2.3.2. NKTR-102 (Nektar Therapeutics)
7.2.3.3. CRLX101 (Cerulean Pharma)
7.2.3.4. Opaxio™ (CTI BioPharma)
 
7.3. Dendrimers: Opportunity Areas
7.3.1. Drug Delivery Systems
7.3.2. Research Applications
7.3.3. Therapeutic Applications
7.3.4. Diagnostic Applications
 
8. CONCLUSION
8.1. The Evolving Era of Polymer Therapeutics Offers Significant Promise to the Pharmaceuticals Market
8.2. Amongst all the Applications, Drug Delivery Holds a Large Opportunity
8.3. The Dendrimer Market is Yet to Unveil itsPotential in the Biomedical Industry
8.4. Polymer Drug Conjugates are Being Exploited for Numerous Therapeutic Areas
8.5. With Success of the Already Commercialized Drugs, the Next Generation of Polymer Drug Conjugates are Poised to Witness an Accelerated Growth
 
9. APPENDIX 1: TABULATED DATA
 
10. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Application of Nanomedicines
Figure 3.2 Nanomedicine Drug Delivery: Applications in Key Therapeutic Areas
Figure 3.3 Challenges Associated with Drug Delivery in Nanotechnology
Figure 3.4 Classification of Nanocarriers
Figure 3.5 Properties of Carbon Nanotubes
Figure 3.6 Properties of Dendrimers
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Disease Area
Figure 4.3 Pipeline Analysis: Distribution by Type of Polymer
Figure 4.4 Pipeline Analysis: Distribution by Type of Drug
Figure 4.5 Polymer Drug Conjugates: Key Players
Figure 5.1 Dendrimers: Advantages
Figure 5.2 Dendrimer versus Linear Polymers
Figure 5.3 Dendrimers: Classification
Figure 5.4 Dendrimers: Types
Figure 5.5 SuperFect® Transfection Reagent: Applications
Figure 5.6 SuperFect® Transfection Reagent: Protocol
Figure 5.7 Polyfect® Transfection Reagent: Protocol
Figure 5.8 PrioFect™: Clinical and Non-Clinical Applications
Figure 5.9 NanoJuice®Transfection Kit: Advantages
Figure 6.1 Polymer Drug Conjugates: Ringsdorf Model
Figure 6.2 Polymer Drug Conjugates: Advantages
Figure 6.3 Application of Polymer Drug Conjugates in Several Indications
Figure 6.4 Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
Figure 6.5 PEGylatedIrinotecan: NKTR-102
Figure 6.6 NKTR-102: Mechanism of Action
Figure 6.7 Advantages of NKTR-102 over Irinotecan
Figure 7.1 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario) 
Figure 7.2 Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
Figure 7.3 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.4 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.5 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.6 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.7 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.8 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.9 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.10 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.11 Collaboration Based Revenues: Illustrative Future Projections
Figure 8.1 Polymer Therapeutics versus Conventional Therapeutics
Figure 8.2 Polymer Drug Conjugates: Emerging Therapeutic Areas
Figure 8.3 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026

List of Tables

Table 3.1 Approved Nanocrystal Drugs
Table 3.2 List of Commercialized Nanomedicines
Table 4.1 Dendrimers: Product List and Classes
Table 4.2 Polymer Drug Conjugates: Development Pipeline
Table 5.1 List of Drugs Loaded in Dendrimers
Table 5.2 List of Commercialized Dendrimers
Table 5.3 Dendritech: List of PAMAM Dendrimers
Table 5.4 Stratus® CS: Type of Biomarkers
Table 5.5 SuperFect™ Transfection Reagent: Product Details
Table 5.6 PolyFect™ Transfection Reagent: Product Details
Table 5.7 PolyFect™ Transfection Reagent: Product Details
Table 5.8 PAMAM: Biotherapeutic Applications
Table 5.9 VivaGel®: Current Status of Development
Table 5.10 VivaGel®: Current Status of Development
Table 5.11 VivaGel®: Clinical Trial Endpoints
Table 5.12 Gadomer-17: Product Specifications
Table 5.13 PPI Dendrimers: Price and Quantity
Table 6.1 Approved Polymer Drug Conjugates
Table 6.2 Polymer Drug Conjugates: Profiled Drugs
Table 6.3 NKTR-102: Current Status of Development
Table 6.4 NKTR-102: Clinical Trials
Table 6.5 NKTR-102: Phase II Clinical Trial Endpoints (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Lung Cancer)
Table 6.6 NKTR-102: Phase II Clinical Trial Endpoints (Glioma, Solid Tumors)
Table 6.7 NKTR-102 versus TPC: Adverse Events
Table 6.8 NKTR-181: Current Status of Development
Table 6.9 NKTR-181: Clinical Trials
Table 6.10 NKTR-181: Clinical Trials
Table 6.11 Opaxio™: Current Status of Development
Table 6.12 Opaxio™: Clinical Studies
Table 6.13 Opaxio™: Clinical Trial Endpoints for Ovarian Epithelial, Peritoneal and Fallopian Tube Cancer
Table 6.14 Opaxio™: Clinical Trial Endpoints for Other Indications
Table 6.15 CRLX101: Current Status of Development
Table 6.16 CRLX101: Clinical Studies
Table 6.17 CRLX101: Clinical Trial Endpoints (Phase II Studies)
Table 6.18 CRLX101: Clinical Trial Endpoints (Phase I/II Studies)
Table 7.1 Polymer Drug Conjugates: Market Potential of Candidates
Table 7.2 NKTR-181: Target Patient Population
Table 7.3 NKTR-102: Target Patient Population
Table 7.4 CRLX101: Target Patient Population
Table 7.5 Opaxio™: Target Patient Population
Table 7.6 Dendrimers: Opportunity Areas
Table 7.7 Drug Delivery Systems: Example List
Table 7.8 Commercialized Dendrimer-Based Kits
Table 9.1 Pipeline Analysis: Distribution by Phase of Development
Table 9.2 Pipeline Analysis: Distribution by Type of Disease Area
Table 9.3 Pipeline Analysis: Distribution by Type of Polymer
Table 9.4 Pipeline Analysis: Distribution by Type of Drug
Table 9.5 Polymer Drug Conjugates: Key Players
Table 9.6 Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
Table 9.7 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario) 
Table 9.8 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Optimistic Scenario)
Table 9.9 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Conservative Scenario)
Table 9.10 Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
Table 9.11 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.12 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.13 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.14 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.15 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.16 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.17 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.18 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.19 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.20 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.21 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.22 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.23 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.24 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.25 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.26 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.27 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.28 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.29 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.30 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.31 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.32 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.33 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.34 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.35 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026

Listed Companies

The following companies and organizations have been mentioned in this report.

  1. 3S Bio 
  2. Abeona Therapeutics
  3. Abramson Cancer Center 
  4. Access Pharmaceuticals
  5. Adama
  6. Ajinomoto Althea
  7. Allergan
  8. Alliance for Clinical Trials in Oncology
  9. Allied Corporation 
  10. Althea Technologies 
  11. Altus Pharmaceuticals
  12. Amgen
  13. Ansell Limited
  14. Arsenal Medical
  15. ASCEND Therapeutics
  16. Ascendis Pharma
  17. Aspen Pharmacare
  18. AstraZeneca
  19. Baxalta
  20. Belrose Pharma
  21. Beth Israel Deaconess Medical Center
  22. BIND Sciences
  23. Biogen
  24. Brown University
  25. Cancer Therapeutics
  26. Carlina Technologies
  27. Cellular Therapeutics
  28. Cerulean Pharma
  29. City of Hope Medical Center 
  30. Clemson University
  31. Colcom
  32. Cosmo Pharmaceuticals
  33. Crealta Pharmaceuticals
  34. CTI BioPharma
  35. CytImmune
  36. Dade Behring 
  37. Dana-Farber Cancer Institute
  38. Dartmouth-Hitchcock Medical Center
  39. DelSiTech
  40. Delta-Fly Pharma
  41. Dendritech Nanotechnologies
  42. Dow Chemical
  43. Durect Corporation
  44. Edge Therapeutics
  45. Eli Lilly
  46. EMD Biosciences
  47. Enzon Pharmaceuticals
  48. Eunice Kennedy Shriver National Institute of Child Health and Human Development 
  49. Eyetech
  50. Ferring
  51. Flamel Technologies 
  52. Genentech
  53. GlaxoSmithKline
  54. Gowan
  55. Gynecologic Oncology Group Foundation 
  56. JenKem Technology 
  57. Landec
  58. Lipotek
  59. M.D.Anderson Cancer Center
  60. MakhteshimAgan
  61. Massachusetts General Hospital
  62. Massachusetts Institute of Technology
  63. Memorial Sloan Kettering Cancer Center
  64. Merck
  65. Mersana Therapeutics
  66. Michigan Nanotechnology Institute for Medicine and Biological Sciences
  67. Mountain View Pharmaceuticals
  68. Mylan
  69. Nanovector
  70. National Cancer Institute
  71. National Heart and Lung Institute 
  72. National Institute of Allergy and Infectious Diseases
  73. National Institutes of Health
  74. National Institute of Mental Health
  75. National Institute on Drug Abuse
  76. National Nanotechnology Initiative
  77. Nektar Therapeutics
  78. NeuroNano Pharma
  79. Novartis
  80. Nufarm
  81. Oakwood Laboratories
  82. Octoplus
  83. Okamoto Industries 
  84. Ontario Institute for Cancer Research
  85. Peptineo
  86. Pfizer
  87. PG-TXL
  88. Pharmacia and Upjohn Company
  89. PolyActiva
  90. Polymer Factory
  91. PolyPid
  92. ProCore Bio Med 
  93. ProLynx
  94. pSivida
  95. Qiagen
  96. Reckitt Benckiser
  97. Rexahn Pharmaceuticals
  98. Roche
  99. Roswell Park Cancer Institute
  100. Sagent Pharmaceuticals
  101. Sanofi-Aventis
  102. Santarus
  103. Savient Pharmaceuticals
  104. Schering Plough
  105. Serina Therapeutics
  106. Shire
  107. Sigma Aldrich
  108. Sitka Biopharma
  109. Sloan-Kettering Institute for Cancer Research
  110. Sonoran Biosciences
  111. Stanford Cancer Institute
  112. Stanford University
  113. Starpharma
  114. Stiefel Laboratories 
  115. Sun Pharma
  116. SUNY Upstate Medical University
  117. SyMO-Chem
  118. Teva Pharmaceutical
  119. The Methodist Hospital System
  120. The State University of New York
  121. UCB Pharma
  122. UNC Lineberger Comprehensive Cancer Center 
  123. University of Chicago 
  124. University of Colorado Boulder
  125. University of Glasgow
  126. University of Illinois
  127. University of Maryland 
  128. University of Pennsylvania
  129. University of Southern California
  130. University of Washington 
  131. US Army Research Laboratory
  132. Weihai CY 
  133. World Health Organization
  134. Wyss Institute 
  135. XstalBio
  136. Yamanouchi Pharmaceutical
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com